SI1701978T1 - Uporaba topnega t-kadherina za zdravljenje presnovnih bolezni - Google Patents
Uporaba topnega t-kadherina za zdravljenje presnovnih bolezniInfo
- Publication number
- SI1701978T1 SI1701978T1 SI200431083T SI200431083T SI1701978T1 SI 1701978 T1 SI1701978 T1 SI 1701978T1 SI 200431083 T SI200431083 T SI 200431083T SI 200431083 T SI200431083 T SI 200431083T SI 1701978 T1 SI1701978 T1 SI 1701978T1
- Authority
- SI
- Slovenia
- Prior art keywords
- disorder
- cadherin
- metabolic disorders
- soluble
- treatment
- Prior art date
Links
- 208000030159 metabolic disease Diseases 0.000 title abstract 3
- 102100024154 Cadherin-13 Human genes 0.000 title abstract 2
- 108010066705 H-cadherin Proteins 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 2
- 206010006895 Cachexia Diseases 0.000 abstract 1
- 208000032928 Dyslipidaemia Diseases 0.000 abstract 1
- 208000035150 Hypercholesterolemia Diseases 0.000 abstract 1
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract 1
- 206010022489 Insulin Resistance Diseases 0.000 abstract 1
- 208000017170 Lipid metabolism disease Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 208000022531 anorexia Diseases 0.000 abstract 1
- 208000037976 chronic inflammation Diseases 0.000 abstract 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 abstract 1
- 206010061428 decreased appetite Diseases 0.000 abstract 1
- 208000017169 kidney disease Diseases 0.000 abstract 1
- 210000004185 liver Anatomy 0.000 abstract 1
- 208000019423 liver disease Diseases 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 238000012216 screening Methods 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
- A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5082—Supracellular entities, e.g. tissue, organisms
- G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Cell Biology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Food Science & Technology (AREA)
- Obesity (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Rheumatology (AREA)
- Child & Adolescent Psychology (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US52695603P | 2003-12-03 | 2003-12-03 | |
PCT/US2004/040363 WO2005057222A2 (en) | 2003-12-03 | 2004-12-02 | Use of t-cadherin as a target |
EP04812804A EP1701978B1 (en) | 2003-12-03 | 2004-12-02 | Use of soluble T-Cadherin for the treatment of metabolic disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
SI1701978T1 true SI1701978T1 (sl) | 2009-08-31 |
Family
ID=34676687
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI200431083T SI1701978T1 (sl) | 2003-12-03 | 2004-12-02 | Uporaba topnega t-kadherina za zdravljenje presnovnih bolezni |
Country Status (18)
Country | Link |
---|---|
US (1) | US20070212686A1 (sl) |
EP (1) | EP1701978B1 (sl) |
JP (1) | JP2007519894A (sl) |
AT (1) | ATE422506T1 (sl) |
AU (1) | AU2004297914A1 (sl) |
CA (1) | CA2546126A1 (sl) |
CY (1) | CY1109014T1 (sl) |
DE (1) | DE602004019451D1 (sl) |
DK (1) | DK1701978T3 (sl) |
ES (1) | ES2320139T3 (sl) |
HR (1) | HRP20090119T3 (sl) |
IL (1) | IL175862A (sl) |
NO (1) | NO20062975L (sl) |
PL (1) | PL1701978T3 (sl) |
PT (1) | PT1701978E (sl) |
RS (1) | RS50754B (sl) |
SI (1) | SI1701978T1 (sl) |
WO (1) | WO2005057222A2 (sl) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2849559A1 (en) | 2006-01-10 | 2007-07-19 | Colgate-Palmolive Company | Methods of modulating cell surface receptors to prevent or reduce inflammation |
TWI405565B (zh) | 2009-04-01 | 2013-08-21 | Colgate Palmolive Co | 口腔用組成物之抗-骨質流失及抗-牙周附連喪失之功效 |
CN102378629B (zh) | 2009-04-01 | 2016-08-17 | 高露洁-棕榄公司 | 用于口部护理组合物的抗生物膜碳酸酯化合物 |
TWI481870B (zh) | 2009-04-01 | 2015-04-21 | Colgate Palmolive Co | 用於軟組織疾病診斷及作為用於口腔保健干預的標靶之蛋白質生物標記 |
RU2492857C2 (ru) | 2009-04-01 | 2013-09-20 | Колгейт-Палмолив Компани | Соединения - производные ментола и их применение в качестве активных системных агентов и агентов для ротовой полости |
GB201312010D0 (en) * | 2013-07-04 | 2013-08-21 | Univ Birmingham | Receptor Agonists |
US11097005B2 (en) | 2014-12-15 | 2021-08-24 | The Brigham And Women's Hospital, Inc. | Use of cadherin-11 antagonists to treat metabolic disorders and/or increase insulin sensitivity |
EP4116711A4 (en) * | 2020-03-03 | 2024-04-10 | Tatsuya Sawamura | ADIPONECTIN QUANTIFICATION METHOD AND ANALYTICAL REAGENT FOR USE IN SAID METHOD |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1023445B1 (de) * | 1997-10-15 | 2005-08-17 | Pharis Biotec GmbH | Cadherin derived growth factor und seine verwendung |
WO1999057149A2 (en) * | 1998-05-05 | 1999-11-11 | Adherex Technologies, Inc. | Compounds and methods for modulating nonclassical cadherin-mediated functions |
US6472367B1 (en) * | 1998-05-05 | 2002-10-29 | Adherex Technologies, Inc. | Compounds and methods for modulating OB-cadherin mediated cell adhesion |
US6680175B2 (en) * | 1998-05-05 | 2004-01-20 | Adherex Technologies, Inc. | Methods for diagnosing and evaluating cancer |
JP2003523192A (ja) * | 2000-02-18 | 2003-08-05 | ビオヴィトルム・アクチボラゲット | Foxc2を発現する肥満のトランスジェニック動物モデル |
AU2001292658A1 (en) * | 2000-09-13 | 2002-03-26 | Eleanor Roosevelt Institute | Method for treatment of insulin resistance in obesity and diabetes |
AU2002240892A1 (en) * | 2001-01-02 | 2002-07-16 | Centre National De La Recherche Scientifique | Protein-protein interactions in adipocyte cells |
WO2004096272A2 (en) * | 2003-04-29 | 2004-11-11 | Cytos Biotechnology Ag | Methods and compositions for modulating the interaction between adiponectin and its receptor |
WO2005049861A2 (en) * | 2003-11-10 | 2005-06-02 | Epigenomics Ag | Method for the analysis of gynaecological cell proliferative disorders |
-
2004
- 2004-12-02 SI SI200431083T patent/SI1701978T1/sl unknown
- 2004-12-02 CA CA002546126A patent/CA2546126A1/en not_active Abandoned
- 2004-12-02 PL PL04812804T patent/PL1701978T3/pl unknown
- 2004-12-02 US US10/553,430 patent/US20070212686A1/en not_active Abandoned
- 2004-12-02 RS RSP-2009/0221A patent/RS50754B/sr unknown
- 2004-12-02 EP EP04812804A patent/EP1701978B1/en not_active Expired - Lifetime
- 2004-12-02 DE DE602004019451T patent/DE602004019451D1/de not_active Expired - Lifetime
- 2004-12-02 JP JP2006542743A patent/JP2007519894A/ja active Pending
- 2004-12-02 PT PT04812804T patent/PT1701978E/pt unknown
- 2004-12-02 AT AT04812804T patent/ATE422506T1/de not_active IP Right Cessation
- 2004-12-02 ES ES04812804T patent/ES2320139T3/es not_active Expired - Lifetime
- 2004-12-02 DK DK04812804T patent/DK1701978T3/da active
- 2004-12-02 WO PCT/US2004/040363 patent/WO2005057222A2/en active Application Filing
- 2004-12-02 AU AU2004297914A patent/AU2004297914A1/en not_active Abandoned
-
2006
- 2006-05-23 IL IL175862A patent/IL175862A/en not_active IP Right Cessation
- 2006-06-26 NO NO20062975A patent/NO20062975L/no not_active Application Discontinuation
-
2009
- 2009-02-24 HR HR20090119T patent/HRP20090119T3/xx unknown
- 2009-04-23 CY CY20091100456T patent/CY1109014T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
JP2007519894A (ja) | 2007-07-19 |
HRP20090119T3 (en) | 2009-04-30 |
RS50754B (sr) | 2010-08-31 |
AU2004297914A1 (en) | 2005-06-23 |
WO2005057222A3 (en) | 2006-02-23 |
EP1701978A2 (en) | 2006-09-20 |
ES2320139T3 (es) | 2009-05-19 |
CA2546126A1 (en) | 2005-06-23 |
US20070212686A1 (en) | 2007-09-13 |
WO2005057222A2 (en) | 2005-06-23 |
PL1701978T3 (pl) | 2009-07-31 |
CY1109014T1 (el) | 2014-07-02 |
ATE422506T1 (de) | 2009-02-15 |
NO20062975L (no) | 2006-06-26 |
PT1701978E (pt) | 2009-03-03 |
EP1701978B1 (en) | 2009-02-11 |
IL175862A0 (en) | 2006-10-05 |
DK1701978T3 (da) | 2009-04-06 |
IL175862A (en) | 2010-11-30 |
DE602004019451D1 (de) | 2009-03-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20090119T3 (en) | Use of soluble t-cadherin for the treatment of metabolic disorders | |
HK1126987A1 (en) | Compounds for the treatment of metabolic disorders | |
WO2007136577A3 (en) | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use | |
MX2009003611A (es) | Compuestos antagonistas del receptor de glucagon, composiciones que contienen dichos compuestos y metodos de uso. | |
WO2008030706A3 (en) | Anti-myostatin antibodies | |
UA76838C2 (uk) | Сполуки, що модулюють активність ppar, та способи їх одержання | |
WO2005077981A3 (en) | Fc POLYPEPTIDES WITH NOVEL Fc LIGAND BINDING SITES | |
TWI370325B (en) | Positive photosensitive resin composition,relief pattern and solid camera element using it | |
HRP20130115T1 (hr) | Postupci lijeäśenja poremeä†aja ili bolesti povezanih sa hiperlipidemijom i hiperkolesterolemijom uz minimizaciju sporednih efekata | |
WO2007067737A3 (en) | Methods and compositions for inhibiting hiv infection | |
TWI350373B (en) | Methods of detecting methyl transferase activity and methods of screening formethyl transferase activity modulators | |
EP1841781A4 (en) | USE OF IL-22 FOR THE TREATMENT OF METABOLISM DISORDER | |
ZA200803532B (en) | Hexahydro-cycloheptapyrazole cannabinoid modulators | |
AU2003221878A8 (en) | G-protein coupled receptor ligands and methods | |
WO2005112933A3 (en) | Substituted organosulfur compounds and methods of using thereof | |
WO2006116660A3 (en) | Methods of inhibiting a gpr23 | |
FR2876586B1 (fr) | Composition pour prevenir ou traiter le stress, notamment les bouffees de stress chronique et permanent | |
CR9479A (es) | Moduladores canabinoides de tetrahidrotiopirano pirazol | |
UA3649U (uk) | Спосіб очищення стічної води від нафтопродуктів | |
TNSN06263A1 (en) | Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders | |
HUP0400762A3 (en) | Pharmaceutical composition for preventing or treating diabetes | |
FI20040879A0 (fi) | Laitteisto partikkeleiden, kuten lastun ja hakkeen, käsittelemiseksi, esimerkiksi seulomiseksi tai sirottelemiseksi | |
HK1083195A1 (en) | Composition for treating hyperlipidemia | |
NO20065800L (no) | IL-13 bindingsmidler |